Clinical Trial Update: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ZN-A-1041 enteric capsules alone or in combination for HER2-positive advanced solid tumors, including HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ZN-A-1041

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Advanced Solid Tumors, HER2-positive Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING